Human β-defensin 3 binds to hemagglutinin B (rHagB), a non-fimbrial adhesin from Porphyromonas gingivalis, and attenuates a pro-inflammatory cytokine response

Immunology and Cell Biology

Volumn 86, Issue 8, 2008, Pages 643-649

  Pingel, Lindsey C ^a   Kohlgraf, Karl G ^a   Hansen, Christopher J ^a   Eastman, Christopher G ^a   Dietrich, Deborah E ^a   Burnell, Kindra K ^a   Srikantha, Rupasree N ^a   Xiao, Xiangjun ^a   Bélanger, Myriam ^b   Progulske Fox, Ann ^b   Cavanaugh, Joseph E ^c   Guthmiller, Janet M ^d   Johnson, Georgia K ^a   Joly, Sophie ^a   Kurago, Zoya B ^e   Dawson, Deborah V ^a   Brogden, Kim A ^a  

^a UNIVERSITY OF IOWA   (United States)

^b UNIVERSITY OF FLORIDA COLLEGE OF DENTISTRY   (United States)

^c UNIVERSITY OF IOWA   (United States)

^d UNIVERSITY OF NORTH CAROLINA   (United States)

^e NEW YORK UNIVERSITY   (United States)

Author keywords

Defensin; HBD3; Innate immunity; Pro inflammatory cytokine suppression

Indexed keywords

BETA DEFENSIN 1; BETA DEFENSIN 2; BETA DEFENSIN 3; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEMAGGLUTININ; INTERLEUKIN 10; INTERLEUKIN 6; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; BACTERIAL STRAIN; BONE MARROW CELL; CELL CULTURE; CONTROLLED STUDY; DENDRITIC CELL; HUMAN; HUMAN CELL; PORPHYROMONAS GINGIVALIS; PROTEIN BINDING; PROTEIN INTERACTION; SURFACE PLASMON RESONANCE;

ADHESINS, BACTERIAL; BETA-DEFENSINS; CYTOKINES; DENDRITIC CELLS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HUMANS; IMMUNITY, INNATE; LECTINS; MAP KINASE SIGNALING SYSTEM; PORPHYROMONAS GINGIVALIS; RECOMBINANT PROTEINS; SURFACE PLASMON RESONANCE;

PORPHYROMONAS GINGIVALIS;

EID: 56249122900     PISSN: 08189641     EISSN: 14401711     Source Type: Journal    
DOI: 10.1038/icb.2008.56     Document Type: Article

References (55)

1. Han J, Ulevitch RJ. Limiting inflammatory responses during activation of innate immunity. Nat Immunol 2005; 6: 1198-1205.
2. Henson PM. Dampening inflammation. Nat Immunol 2005; 6: 1179-1181.
3. Mayer L, Shao L. Therapeutic potential of oral tolerance. Nat Rev Immunol 2004; 4: 407-419.
4. Anderson P. Post-transcriptional control of cytokine production. Nat Immunol 2008; 9: 353-359.
5. Fenner JE, Starr R, Cornish AL, Zhang JG, Metcalf D, Schreiber RD et al. Suppressor of cytokine signaling 1 regulates the immune response to infection by a unique inhibition of type I interferon activity. Nat Immunol 2006; 7: 33-39.
6. Bogoyevitch MA, Fairlie DP. A new paradigm for protein kinase inhibition: blocking phosphorylation without directly targeting ATP binding. Drug Discov Today 2007; 12: 622-633.
7. Selsted ME, Ouellette AJ. Mammalian defensins in the antimicrobial immune response. Nat Immunol 2005; 6: 551-557.
8. Brogden KA. Antimicrobial peptides: pore formers or metabolic inhibitors in bacteria? Nat Rev Microbiol 2005; 3: 238-250.
9. Ganz T. Defensins: antimicrobial peptides of innate immunity. Nat Rev Immunol 2003; 3: 710-720.
10. Schutte BC, Mitros JP, Bartlett JA, Walters JD, Jia HP, Welsh MJ et al. Discovery of five conserved β-defensin gene clusters using a computational search strategy. Proc Natl Acad Sci USA 2002; 99: 2129-2133.
11. Lehrer RI. Primate defensins. Nat Rev Microbiol 2004; 2: 727-738.
12. Hollox EJ, Armour JA, Barber JC. Extensive normal copy number variation of a beta-defensin antimicrobial-gene cluster. Am J Hum Genet 2003; 73: 591-600.
13. Chen Q, Book M, Fang X, Hoeft A, Stuber F. Screening of copy number polymorphisms in human beta-defensin genes using modified real-time quantitative PCR. J Immunol Methods 2006; 308: 231-240.
14. Schibli DJ, Hunter HN, Aseyev V, Starner TD, Wiencek JM, McCray Jr PB et al. The solution structures of the human beta-defensins lead to a better understanding of the potent bactericidal activity of HBD3 against Staphylococcus aureus. J Biol Chem 2002; 277: 8279-8289.
15. Garcia JR, Jaumann F, Schulz S, Krause A, Rodriguez-Jimenez J, Forssmann U et al. Identification of a novel, multifunctional beta-defensin (human beta-defensin 3) with specific antimicrobial activity. Its interaction with plasma membranes of Xenopus oocytes and the induction of macrophage chemoattraction. Cell Tissue Res 2001; 306: 257-264.
16. Harder J, Bartels J, Christophers E, Schroder JM. Isolation and characterization of human β-Defensin-3, a novel human inducible peptide antibiotic. J Biol Chem 2001; 276: 5707-5713.
17. Harder J, Bartels J, Christophers E, Schroder J-M. A peptide antibiotic from human skin. Nature 1997; 387: 861-862.
18. Joly S, Organ CC, Johnson GK, McCray Jr PB, Guthmiller JM. Correlation between betadefensin expression and induction profiles in gingival keratinocytes. Mol Immunol 2005; 42: 1073-1084.
19. Dunsche A, Acil Y, Dommisch H, Siebert R, Schroder JM, Jepsen S. The novel human beta-defensin-3 is widely expressed in oral tissues. Eur J Oral Sci 2002; 110: 121-124.
20. Hazrati E, Galen B, Lu W, Wang W, Ouyang Y, Keller MJ et al. Human alpha- and beta-defensins block multiple steps in herpes simplex virus infection. J Immunol 2006; 177: 8658-8666.
21. Feng Z, Dubyak GR, Lederman MM, Weinberg A. Cutting edge: human beta defensin 3 - a novel antagonist of the HIV-1 coreceptor CXCR4. J Immunol 2006; 177: 782-786.
22. Quinones-Mateu ME, Lederman MM, Feng Z, Chakraborty B, Weber J, Rangel HR et al. Human epithelial beta-defensins 2 and 3 inhibit HIV-1 replication. Aids 2003; 17: F39-F48.
23. Joly S, Maze C, McCray Jr PB, Guthmiller JM. Human beta-defensins 2 and 3 demonstrate strain-selective activity against oral microorganisms. J Clin Microbiol 2004; 42: 1024-1029.
24. Yang D, Biragyn A, Kwak LW, Oppenheim JJ. Mammalian defensins in immunity: more than just microbicidal. Trends Immunol 2002; 23: 291-296.
25. Chen X, Niyonsaba F, Ushio H, Hara M, Yokoi H, Matsumoto K et al. Antimicrobial peptides human beta-defensin (hBD)-3 and hBD-4 activate mast cells and increase skin vascular permeability. Eur J Immunol 2007; 37: 434-444.
26. Takahashi Y, Davey M, Yumoto H, Gibson III FC, Genco CA. Fimbria-dependent activation of pro-inflammatory molecules in Porphyromonas gingivalis infected human aortic endothelial cells. Cell Microbiol 2006; 8: 738-757.
27. Zhang P, Martin M, Michalek SM, Katz J. Role of mitogen-activated protein kinases and NF-kappaB in the regulation of pro-inflammatory and anti-inflammatory cytokines by Porphyromonas gingivalis hemagglutinin B. Infect Immun 2005; 73: 3990-3998.
28. Kinane DF, Demuth DR, Gorr SU, Hajishengallis GN, Martin MH. Human variability in innate immunity. Periodontol 2000 2007; 45: 14-34.
29. Song H, Belanger M, Whitlock J, Kozarov E, Progulske-Fox A. Hemagglutinin B is involved in the adherence of Porphyromonas gingivalis to human coronary artery endothelial cells. Infect Immun 2005; 73: 7267-7273.
30. Progulske-Fox A, Tumwasorn S, Holt SC. The expression and function of a Bacteroides gingivalis hemagglutinin gene in Escherichia coli. Oral Microbiol Immunol 1989; 4: 121-131.
31. Progulske-Fox A, Tumwasorn S, Lepine G, Whitlock J, Savett D, Ferretti JJ et al. The cloning, expression and sequence analysis of a second Porphyromonas gingivalis gene that codes for a protein involved in hemagglutination. Oral Microbiol Immunol 1995; 10: 311-318.
32. Lepine G, Ellen RP, Progulske-Fox A. Construction and preliminary characterization of three hemagglutinin mutants of Porphyromonas gingivalis. Infect Immun 1996; 64: 1467-1472.
33. Han N, Lepine G, Whitlock J, Wojciechowski L, Progulske-Fox A. The Porphyromonas gingivalis prtP/kgp homologue exists as two open reading frames in strain 381. Oral Dis 1998; 4: 170-179.
34. Veith PD, Talbo GH, Slakeski N, Dashper SG, Moore C, Paolini RA et al. Major outer membrane proteins and proteolytic processing of RgpA and Kgp of Porphyromonas gingivalis W50. Biochem J 2002; 363: 105-115.
35. Katz J, Black KP, Michalek SM. Host responses to recombinant hemagglutinin B of Porphyromonas gingivalis in an experimental rat model. Infect Immun 1999; 67: 4352-4359.
36. Zhang P, Martin M, Yang QB, Michalek SM, Katz J. Role of B7 costimulatory molecules in immune responses and T-helper cell differentiation in response to recombinant HagB from Porphyromonas gingivalis. Infect Immun 2004; 72: 637-644.
37. Watanabe K, Yilmaz O, Nakhjiri SF, Belton CM, Lamont RJ. Association of mitogen-activated protein kinase pathways with gingival epithelial cell responses to Porphyromonas gingivalis infection. Infect Immun 2001; 69: 6731-6737.
38. Lu Q, Samaranayake LP, Darveau RP, Jin L. Expression of human beta-defensin-3 in gingival epithelia. J Periodontal Res 2005; 40: 474-481.
39. Saitoh M, Abiko Y, Shimabukuro S, Kusano K, Nishimura M, Arakawa T et al. Correlated expression of human beta defensin-1, -2 and -3 mRNAs in gingival tissues of young children. Arch Oral Biol 2004; 49: 799-803.
40. Bissell J, Joly S, Johnson GK, Organ CC, Dawson D, BMcCray PJ et al. Expression of beta-defensins in gingival health and in periodontal disease. J Oral Pathol Med 2004; 33: 278-285.
41. Ghosh SK, Gerken TA, Schneider KM, Feng Z, McCormick TS, Weinberg A. Quantification of human beta-defensin-2 and -3 in body fluids: application for studies of innate immunity. Clin Chem 2007; 53: 757-765.
42. Tao R, Jurevic RJ, Coulton KK, Tsutsui MT, Roberts MC, Kimball JR et al. Salivary antimicrobial peptide expression and dental caries experience in children. Antimicrob Agents Chemother 2005; 49: 3883-3888.
43. Dale BA, Tao R, Kimball JR, Jurevic RJ. Oral antimicrobial peptides and biological control of caries. BMC Oral Health 2006; 6 (Suppl 1): S13.
44. Okuda K, Yamamoto A, Naito Y, Takazoe I, Slots J, Genco RJ. Purification and properties of hemagglutinin from culture supernatant of Bacteroides gingivalis. Infect Immun 1986; 54: 659-665.
45. Johnson GL, Lapadat R. Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science 2002; 298: 1911-1912.
46. Wehkamp J, Salzman NH, Porter E, Nuding S, Weichenthal M, Petras RE et al. Reduced Paneth cell alpha-defensins in ileal Crohn's disease. Proc Natl Acad Sci USA 2005; 102: 18129-18134.
47. Aldred PM, Hollox EJ, Armour JA. Copy number polymorphism and expression level variation of the human alpha-defensin genes DEFA1 and DEFA3. Hum Mol Genet 2005; 14: 2045-2052.
48. Wehkamp J, Schmid M, Fellermann K, Stange EF. Defensin deficiency, intestinal microbes, and the clinical phenotypes of Crohn's disease. J Leukoc Biol 2005; 77: 460-465.
49. Dork T, Stuhrmann M. Polymorphisms of the human beta-defensin-1 gene. 1998; 12: 171-173.
50. Linzmeier RM, Ganz T. Human defensin gene copy number polymorphisms: comprehensive analysis of independent variation in alpha- and beta-defensin regions at 8p22-p23. Genomics 2005; 86: 423-430.
51. Fellermann K, Wehkamp J, Herrlinger KR, Stange EF. Crohn's disease: a defensin deficiency syndrome? Eur J Gastroenterol Hepatol 2003; 15: 627-634.
52. Boniotto M, Hazbon MH, Jordan WJ, Lennon GP, Eskdale J, Alland D et al. Novel hairpin-shaped primer assay to study the association of the -44 single-nucleotide polymorphism of the DEFB1 gene with early-onset periodontal disease. Clin Diagn Lab Immunol 2004; 11: 766-769.
53. Vankeerberghen A, Scudiero O, De Boeck K, Macek Jr M, Pignatti PF, Van Hul N et al. Distribution of human beta-defensin polymorphisms in various control and cystic fibrosis populations. Genomics 2005; 85: 574-581.
54. Kohler JJ, Pathangey L, Hasona A, Progulske-Fox A, Brown TA. Long-term immunological memory induced by recombinant oral Salmonella vaccine vectors. Infect Immun 2000; 68: 4370-4373.
55. Conover W. Practical Nonparametric Statistics, Edn, 3rd edn. Wiley: New York, 1999.